Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Trial Identifier: D8151C00001
Sponsor: AstraZeneca
Start Date: December 2021
Primary Completion Date: October 2024
Study Completion Date: December 2025
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, ON Toronto, ON, CA, M5G 2M9
CA, ON Toronto, ON, CA, M4N 3M5
CA, Ontario Barrie, Ontario, CA, L4M 6M2
ES Badalona, ES, 08916
ES Barcelona, ES, 08035
ES Madrid, ES, 28050
ES Madrid, ES, 28041
ES Madrid, ES, 28034
ES Madrid, ES, 28027
ES Majadahonda, ES, 28222
ES Pamplona, ES, 31008
KR Seongnam-si, KR, 13620
KR Seongnam-Si, KR, 463-712
KR seoul, KR, 06351
KR Seoul, KR, 03722
KR Seoul, KR, 06591
KR Seoul, KR, 05505
KR Seoul, KR, 03080
US, CA La Jolla, CA, US, 92037
US, CA Los Angeles, CA, US, 90025
US, CA Orange, CA, US, 92868
US, CA Ventura, CA, US, 93003
US, GA Atlanta, GA, US, 30318
US, ID Coeur D Alene, ID, US, 83814
US, MA Boston, MA, US, 02114
US, MI Ann Arbor, MI, US, 48109
US, MI Grand Rapids, MI, US, 49503
US, NY Buffalo, NY, US, 14263
US, NY New York, NY, US, 10065
US, OR Portland, OR, US, 97239
US, TX San Antonio, TX, US, 78229
US, VA Charlottesville, VA, US, 22908
US, WA Seattle, WA, US, 98195
US, WI Madison, WI, US, 53792